Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

After trialing a "single patient Investigational New Drug" (IND) which allowed him access to BPM31510, Chase has been cancer-free for 17 years. This year marks the 18th anniversary of my ongoing ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Launch of Hyde Park Discovery between UChicago, Deerfield Management to accelerate research into life-saving treatments ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Please provide your email address to receive an email when new articles are posted on ... episodes and nighttime blood pressure (BP). The drug’s safety profile in this specific patient ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...